Bottom line
PHSZX vs XLV: the short answer
PHSZX (PGIM Jennison Health Sciences Fund) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
XLV is cheaper at 0.08% vs 0.88% — a difference of $80 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +7.0% for PHSZX (reporting dates differ).
Updated Nov 19, 2026
PHSZX vs XLV side by side
| PHSZX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | PGIM (Prudential) | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.88% | 0.08% |
| Annual cost per $10k | $88 | $8 |
| 10-yr cost on $10k (prospectus) | $1,084 | $103 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +19.6% | +14.5% |
| 5-yr return (annualized) | +7.0% | +8.1% |
| 10-yr return (annualized) | +9.8% | +9.8% |
| Best quarter | +29.7% | +14.5% |
| Worst quarter | −20.5% | −12.7% |
| Net assets (fund) | $1.4B | $40.6B |
| Number of holdings | 55 | 65 |
| Portfolio turnover | 81% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSZX | XLV | Difference |
|---|---|---|---|
| 2024 | +19.6% | +2.5% | +17.1% |
| 2023 | +8.8% | +2.0% | +6.8% |
| 2022 | +12.6% | −2.1% | +14.7% |
| 2021 | −10.1% | +25.9% | −36.0% |
| 2020 | +6.3% | +13.3% | −7.0% |
| 2019 | +41.7% | +20.7% | +21.0% |
| 2018 | +18.6% | +6.3% | +12.3% |
| 2017 | −3.4% | +21.7% | −25.1% |
| 2016 | +31.4% | −2.8% | +34.2% |
Source: Fund prospectus bar charts
Holdings overlap
9 of PHSZX's top 25 holdings also appear in XLV's top 25.
| Holding | PHSZX | XLV |
|---|---|---|
| Eli Lilly & Company | 17.35% | 16.51% |
| Merck & Company Inc | 6.06% | 5.52% |
| Unitedhealth Group Inc | 5.87% | 6.57% |
| Thermo Fisher Scientific Inc | 4.56% | 3.24% |
| Vertex Pharmaceuticals Inc | 3.37% | 2.19% |
| Danaher Corp | 3.28% | 2.09% |
| Intuitive Surgical Inc | 3.07% | 2.45% |
| Cvs Health Corp | 2.52% | 2.30% |
| Stryker Corp | 2.16% | 1.89% |
Source: SEC Form N-PORT
PHSZX top 10
- Eli Lilly & Company — 17.35%
- Merck & Company Inc — 6.06%
- Unitedhealth Group Inc — 5.87%
- Thermo Fisher Scientific Inc — 4.56%
- Argenx Se — 3.55%
- Vertex Pharmaceuticals Inc — 3.37%
- Danaher Corp — 3.28%
- Intuitive Surgical Inc — 3.07%
- Lonza Group Ag — 3.02%
- Cvs Health Corp — 2.52%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between PHSZX and XLV?
Which is cheaper, PHSZX or XLV?
Should I own both PHSZX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.